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The arrival of genomic medicine to the clinic is only the 
beginning of the journey
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This month we are delighted to feature an important article titled “Implementing Genomic 
Medicine in the Clinic: The Future is Here.”1 In this article, Teri Manolio and a veritable 
Who’s Who of genomic medicine nicely articulate the near-term promise of genomic 
medicine and lay out a number of current efforts being pursued at leading institutions, all 
designed to implement genomics in patient care. The authors detail many of the challenges 
to using genomics in clinical care and highlight four specific applications of genomics: 
tumor-based screening, family history–directed decision support, pharmacogenomics (PGx), 
and diagnostic genome sequencing to “demonstrate that genomic medicine is no longer on 
the threshold; it has arrived.”
In doing so, the authors point toward many of the ways in which genomic medicine may 
ultimately benefit patients and the practice of medicine. They have not neglected to address 
many of the challenges and are not remiss in making multiple calls for an evidence-based 
approach to its implementation. Here, we wish to amplify these calls and emphasize the 
necessary primacy of evidence.
The speed with which genomics has become clinically relevant and the tremendous power of 
this new technology led to its rapid implementation in a variety of clinical settings. But as 
Manolio et al.1 remind us in their article, we must not assume that good ideas automatically 
translate into improved patient care. Their article should not be taken simply as a roadmap to 
genomic implementation for its own sake. Rather, it should serve as a roadmap for how to 
implement genomic medicine in a way that ultimately gets us to our real goal—a firm 
foundation of evidence-based genomic medicine.
In other words, the “arrival” of genomic medicine at its current stage represents less than 
half the journey. A few years ago, Khoury et al.2 identified four phases of genomics 
translational research starting with genome-based discoveries and leading to improved 
population health outcomes. In the context of genomic medicine, we have indeed arrived at 
the first destination (translational phase 1 (T1): from bench to bedside). In the T2 phase of 
translation, we must now figure out whether and how genomic analysis can actually improve 
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patient outcomes and, specifically, which of the many promising facets of this new field 
offer real and tangible improvements in care. We should not prematurely skip this 
evaluation phase in favor of implementation research (T3) and outcomes research (T4). 
After all, from novel imaging modalities to new drugs, medicine is replete with tantalizing 
new approaches to patient care that promise marvels. Yet, the lessons of the history of 
medicine are clear: prematurely and casually implementing attractive technologies and 
strategies without meeting the hard and high bar of clearly improved outcomes is literally 
dangerous. The reflexive use of hormone replacement therapy3 in postmenopausal women 
and whole-scale screening of men for prostate cancer by prostate-specific antigen 
measurement,
A prominent application of genomics to patient care highlighted by Manolio et al.1, is the 
use of whole-genome sequencing to diagnose enigmatic conditions that have a high 
likelihood of a primary genetic etiology. This application is already becoming widespread; 
given that diagnosis is the lynchpin of clinical care, the bar that must be met for its 
implementation is low. It need only be shown that genomic approaches indeed yield 
answers, an outcome that in and of itself is of value to patients, clinicians, and researchers 
alike. What must now be defined are the specific clinical features of a patient’s presentation 
that indicate that this technology is likely to yield a definitive diagnosis. In doing so, we will 
have a roadmap to guide clinicians as to whether it is likely to be worthwhile to bring 
genomics to bear on a given patient. This is no different from what must be done for any 
medical test. After all, magnetic resonance imaging is a marvelous and highly useful 
medical test. But we hear few (sensible) calls to obtain magnetic resonance imaging on all of 
our patients. Rather, research has defined those specific clinical settings in which a magnetic 
resonance imaging is likely to be productive. Therefore, genome-scale sequencing of 
patients will likely best be applied in specific and defined circumstances. Our field now 
faces the exciting challenge of defining those circumstances.
Other applications of genomics highlighted by Manolio et al.1 include the tantalizing 
prospects of whole-genome tumor sequencing to guide cancer therapeutics and the use of 
preemptive PGx testing to guide the selection of drugs. For both applications, evidence must 
now be sought that shows patient outcomes improve before they are routinely employed; 
something that is hardly a foregone conclusion. On the tumor genomics side, we have had 
success stories with HER2 and EGFR to drive therapeutics for a subset of patients with 
cancer. Nevertheless, the sole example of germline PGx testing that has been recommended 
by an evidence-based panel5 as standard of care (HLA-B*5701 testing before prescribing 
abacavir) is supported by a dramatic—and virtually unique—odds ratio for association 
between an adverse event and a specific genotype, coupled with the existence of alternative 
treatment modalities. For other examples, even the most compelling scenarios in which PGx 
may improve outcomes remain largely speculative. Although many of us hope that CYP2C9 
and VKORC1 genotyping may result in safer anticoagulation therapy or that clopidogrel can 
be more effectively used with PGx information in hand, no evidence-based groups have 
recommended their routine clinical use. Likewise, the use of whole-genome sequencing of 
tumors is an appealing application and could well prove to save lives and money. But it is 
not enough to hope; we must demonstrate that this is the case through sober, well-designed 
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studies designed not to “show” that genomic medicine is wonderful but to simply and 
dispassionately investigate whether it really is. This is especially true in an era in which 
overtesting is increasingly being appreciated as a considerable threat to good outcomes and 
affordable care.6
We wish it were not so. It would be far cheaper and far easier if a high threshold for 
evidence with regard to outcomes was not needed. But the stakes are high. Premature 
implementation of even highly appealing medical modalities can carry a high price tag in 
terms of patient suffering and cost. In addition, although the cost of accruing such evidence 
is indeed high, it is trivial as compared with the cost of blind and uninformed 
implementation.
Part and parcel to the accrual of evidence is the development of new and innovative ways to 
evaluate evidence. As Manolio et al.1 articulate, we will never have enough time or money 
to conduct randomized controlled trials for each and every genotype in those myriad clinical 
settings in which genomics is likely to be relevant. We thus need to arrive at novel 
approaches for comparative effectiveness research,7 stakeholder engagement,8 and 
knowledge integration.9
Manolio et al.1 also address the thorny issue of cost, cogently arguing that new models are 
required to ensure adequate reimbursement for genomic analysis and implementation. Here 
too, evidence is the answer. When evidence of benefit is clearly demonstrated for a given 
approach, adequate reimbursement is far easier to secure. We must eschew “pushing” 
genomics into medicine because of our enthusiasm and hopes of its promise. Rather, we 
must focus on accruing evidence so that genomics—along with reimbursement—is “pulled” 
into patient care by demand from knowledgeable nongenetic physicians who clamor for its 
application to their patients because it has been shown to be a useful tool.
Critical to arriving at our ultimate destination—improved health outcomes as a result of 
implementation of genomic medicine— will be the construction of a genome-friendly 
electronic medical record. Manolio et al.1 rightly spend considerable time discussing the 
nature of the electronic medical record that will be required in a genomic age. It bears 
emphasizing that integrating genomic patient data into the electronic medical record should 
not be seen as an end in itself. Rather, it is a necessary first step that will then facilitate an 
evaluation of whether it can be of benefit to our patients.
The National Institutes of Health and especially the National Human Genome Research 
Institute have made an admirable start to facilitating the next phase of our genomic medicine 
journey. Through their funding of consortia such as those focused on clinical exploratory 
sequencing, medical genomic demonstration projects, and a new request for applications 
focused on defining clinically meaningful variation in the human genome, they are 
husbanding their resources wisely and maintaining a strong focus on evidence. In our 
appropriately celebratory mood regarding the “arrival” of genomic medicine, let’s not forget 
that we still have a long way to go. The hard (and exciting) work of figuring out just how 
these wondrous new technologies can benefit our patients has only begun.
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